Herbai G, Ljunghall S
Horm Metab Res. 1984 Jul;16(7):374-6. doi: 10.1055/s-2007-1014794.
In eight patients with primary hyperparathyroidism (HPT) the laboratory effects of cyclofenil, which is a synthetic stilbestrol derivative with weak feminizing effects, were studied over a period of 5-13 weeks. In all the patients there were during treatment clear reductions of the serum calcium levels as well as the urinary excretions of calcium and hydroxyproline. These findings are in accordance with earlier reports that oestrogens reduce bone resorption mediated by parathyroid hormone. It has previously been demonstrated that cyclofenil can be given, on other indications, for several years to both male and female patients without oestrogenic side-effects. This pilot study, therefore, indicates that treatment with cyclofenil might be of value in some cases of primary HPT where surgery is not considered.
在8例原发性甲状旁腺功能亢进症（HPT）患者中，对环芬尼（一种具有微弱女性化作用的合成己烯雌酚衍生物）的实验室效应进行了为期5至13周的研究。在所有患者中，治疗期间血清钙水平以及钙和羟脯氨酸的尿排泄量均明显降低。这些发现与早期关于雌激素可减少甲状旁腺激素介导的骨吸收的报道一致。此前已证明，环芬尼可用于其他适应症，给予男性和女性患者数年而无雌激素副作用。因此，这项初步研究表明，对于一些不考虑手术的原发性HPT病例，环芬尼治疗可能有价值。
